Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3a lot-to-lot consistency study of an investigational varicella vaccine versus Varivax in healthy children 12 to 15 months old
2024-515869-33-00Phase 3Authorised
- Sponsor
- GSK
- Start
- May 2025
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, Live Biotherapeutic Products → Microbiome Therapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 11
01
Overview
Phase 3, randomised, single-blind trial of GSKVX000000025896 and varicella virus vaccine live in chickenpox (5 arms), sponsored by GSK. Primary endpoints: Percentage of participants with seroresponse to VZV anti-gE IgG for the 3 lots of investigational vaccine, Geometric mean concentration of anti-VZV gE IgG for the 3 lots of investigational vaccine and 2 more. Planned start May 2025; status: authorised.
02
Drugs
GSKVX000000025896varicella virus vaccine live
03
Conditions
chickenpox
Beyond the preview
Go deeper on 2024-515869-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515869-33-00.